3
Clinical Trials associated with KSP-0243An Early Phase 2 Clinical Study of KSP-0243 in Patients With Mild to Moderate Active Ulcerative Colitis
A phase 2a, randomized, double-blind, placebo-controlled, multicenter, parallel-group study to administer KSP-0243 or a placebo once daily after breakfast for 8 weeks in 100 patients with mild to moderate active ulcerative colitis.
/ Not yet recruitingPhase 2 A Phase IIa, randomized, double-blind, placebo-controlled, multicentre study of a once daily multiple oral administration of KSP-0243 in patients with mild-to-moderate ulcerative colitis
A phase I clinical study of KSP-0243 in Japanese and Caucasian healthy adult males
Start Date18 Jan 2021 |
Sponsor / Collaborator- |
100 Clinical Results associated with KSP-0243
100 Translational Medicine associated with KSP-0243
100 Patents (Medical) associated with KSP-0243
100 Deals associated with KSP-0243